shiseido future solution lx infinite treatment primer

Generic: titanium dioxide, octinoxate, and ensulizole

Labeler: shiseido americas corporation
NDC Directory HUMAN OTC DRUG OTC MONOGRAPH DRUG Inactive Finished

Drug Facts

Product Profile

Brand Name shiseido future solution lx infinite treatment primer
Generic Name titanium dioxide, octinoxate, and ensulizole
Labeler shiseido americas corporation
Dosage Form EMULSION
Routes
TOPICAL
Active Ingredients

ensulizole .428 g/40mL, octinoxate 1.71 g/40mL, titanium dioxide 1.77 g/40mL

Manufacturer
SHISEIDO AMERICAS CORPORATION

Identifiers & Regulatory

Product NDC 58411-657
Product ID 58411-657_47b9be75-c9c2-b19a-e063-6294a90a3412
Product Type HUMAN OTC DRUG
Marketing Category OTC MONOGRAPH DRUG
Application Number M020
Listing Expiration 2027-12-31
Marketing Start 2021-05-01

Normalized Code Variants

Searchable formats for this product NDC code

Digits Only 58411657
Hyphenated Format 58411-657

Supplemental Identifiers

UNII
9YQ9DI1W42 4Y5P7MUD51 15FIX9V2JP

Packaging Origin

Original Packager
true

Resolved Product View

Precedence rule: structured NDC data is preferred, falling back to linked label metadata when unavailable. Source tags show the origin of each value.

Resolved Identity

Brand Name shiseido future solution lx infinite treatment primer (source: ndc)
Generic Name titanium dioxide, octinoxate, and ensulizole (source: ndc)
Application Number M020 (source: ndc)
Routes
TOPICAL
source: ndc

Resolved Composition

Strengths
  • .428 g/40mL
  • 1.71 g/40mL
  • 1.77 g/40mL
source: ndc
Packaging
  • 1 TUBE in 1 CARTON (58411-657-10) / 40 mL in 1 TUBE
source: ndc

Packages (1)

58411-657-10 1 TUBE in 1 CARTON (58411-657-10) / 40 mL in 1 TUBE

Ingredients (3)

ensulizole (.428 g/40mL) octinoxate (1.71 g/40mL) titanium dioxide (1.77 g/40mL)

Linked Drug Pages (1)

SHISEIDO FUTURE Solution LX INFINITE TREATMENT PRIMER ndc-match (0.9)

Raw FDA Data

View complete raw FDA NDC JSON payload 
{"route": ["TOPICAL"], "spl_id": "47b9be75-c9c2-b19a-e063-6294a90a3412", "openfda": {"unii": ["9YQ9DI1W42", "4Y5P7MUD51", "15FIX9V2JP"], "spl_set_id": ["ff088b0c-27c9-4ea8-bf94-6261378c7190"], "manufacturer_name": ["SHISEIDO AMERICAS CORPORATION"], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "1 TUBE in 1 CARTON (58411-657-10)  / 40 mL in 1 TUBE", "package_ndc": "58411-657-10", "marketing_start_date": "20210501"}], "brand_name": "SHISEIDO FUTURE Solution LX INFINITE TREATMENT PRIMER", "product_id": "58411-657_47b9be75-c9c2-b19a-e063-6294a90a3412", "dosage_form": "EMULSION", "product_ndc": "58411-657", "generic_name": "TITANIUM DIOXIDE, OCTINOXATE, and ENSULIZOLE", "labeler_name": "SHISEIDO AMERICAS CORPORATION", "product_type": "HUMAN OTC DRUG", "brand_name_base": "SHISEIDO FUTURE Solution LX INFINITE TREATMENT PRIMER", "active_ingredients": [{"name": "ENSULIZOLE", "strength": ".428 g/40mL"}, {"name": "OCTINOXATE", "strength": "1.71 g/40mL"}, {"name": "TITANIUM DIOXIDE", "strength": "1.77 g/40mL"}], "application_number": "M020", "marketing_category": "OTC MONOGRAPH DRUG", "marketing_start_date": "20210501", "listing_expiration_date": "20271231"}